

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for treating hepatitis and immunological disorders comprising a therapeutically effective amount of at least one of the botanical plants *Actaea rubra*, *Anemone hepatica*, *Anemone nemorosa*, *Nigella sativa*, and *Ranunculus arvensis*, or extracts thereof, and a pharmaceutically acceptable carrier.
2. A pharmaceutical composition comprising a therapeutically effective amount of *Anemone hepatica* and/or *Nigella sativa* for treating hepatic and immunological disorders.
3. A composition according to claim 1, wherein the composition's extract is concentrated and sterilized rendering a sterile preparation with a concentration of not less than 20% weight per volume.
4. A composition according to claim 1, wherein the composition is in a form of a tablet or capsule.
5. A composition according to claim 1, wherein the composition is in a form of a liquid or suspension.
6. A composition according to claim 1, wherein the composition is in a form of a sterile preparation for intra-muscular, subcutaneous, or intra-venous injection.
7. A composition according to claim 1, wherein the composition is in a form of nasal spray.

8. A composition according to claim 1, wherein the composition is in a form of a topical application.
9. A composition according to claim 1, wherein the composition is in a form of a transdermal system.
10. A composition according to claim 1, wherein the composition is in a form of suppository.
11. A method of treating hepatic disorders, comprising administration of a composition according to claim 1 to a patient requiring such treatment.
12. A method of treating hepatic disorders, without adversely affecting the hemoglobin blood level, comprising administration of a composition according to claim 1 to a patient requiring such treatment.
13. A method of treating hepatic disorders caused by hepatitis C virus infection, comprising administration of a composition according to claim 1 to patients with clinical stages 0/6, 1/6, 2/6, and 3/6, with corresponding hepatic activity index ranging from 1/18 to 9/18, requiring such treatment.
14. A method of treating hepatic disorders caused by hepatitis C virus infection, comprising administration of a composition according to claim 1 to patients with clinically advanced stages, i.e. 4/6, 5/6, and 6/6, with corresponding hepatic activity index ranging from 7/18 to 13/18, requiring such treatment.
15. A method according to claim 11, wherein the hepatic disorders result from chronic hepatitis.
16. A method according to claim 11, wherein the hepatic disorders result from genotypes I, II, III, IV.

17. A method of treating immunological disorders, comprising administration of a composition according to claim 1 to a patient with a compromised immune system requiring such treatment.
18. A method of increasing the natural killer cell populations, comprising administration of a composition according to claim 1 to a patient requiring such treatment.
19. A method of increasing the blood platelet count, comprising administration of a composition according to claim 1 to a patient requiring such treatment.
20. A method of decreasing the viral load of liver-cancer patients, comprising administration of a composition according to claim 1 to a patient requiring such treatment.
21. A method according to any of claims 11, 12, 13, 14, 17, 18, 19, or 20, wherein the treatment is therapeutic.
22. A method according to any of claims 11, 12, 13, 14, 17, 18, 19, or 20, wherein the treatment is prophylactic.